Trial · NCT04030026
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs) | NAL ER | 35 | Participants | ||
| Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs) | Placebo | 26 | Participants | ||
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | NAL ER | Urinalysis | 0 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | Placebo | Urinalysis | 0 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | NAL ER | Hematology | 1 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | Placebo | Hematology | 0 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | NAL ER | Serum Chemistry | 1 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | Placebo | Serum Chemistry | 1 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | NAL ER | Coagulation | 0 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | Placebo | Coagulation | 1 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | NAL ER | Liver Function Parameters | 0 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | Placebo | Liver Function Parameters | 0 | Participants | |
| Number of Participants With Clinically Significant Changes in Vital Sign Parameters | NAL ER | 0 | Participants | ||
| Number of Participants With Clinically Significant Changes in Vital Sign Parameters | Placebo | 0 | Participants | ||
| Number of Participants With Clinically Significant Changes in Physical Examination Parameters | NAL ER | 0 | Participants | ||
| Number of Participants With Clinically Significant Changes in Physical Examination Parameters | Placebo | 0 | Participants | ||
| Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) | NAL ER | 1 | Participants | ||
| Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) | Placebo | 1 | Participants | ||
| Change From Baseline in Forced Vital Capacity (FVC) at Day 21 | NAL ER | -2.3 | Standard Deviation 5.58 | litre(s) | |
| Change From Baseline in Forced Vital Capacity (FVC) at Day 21 | Placebo | -1.0 | Standard Deviation 5.56 | litre(s) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04030026/results